Associate degree or above in biology, biochemistry, medical science, biophysics, or other related discipline....
From Indeed - Fri, 08 Jun 2018 20:43:46 GMT - View all Milwaukee, WI jobs

Funding Opportunity PA-18-825 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals.

Funding Opportunity PA-18-826 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) invites applications for new exploratory research projects (R21) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals.

Funding Opportunity PA-18-824 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) invites applications for new exploratory research projects (R21) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long- term Effects of Reducing Intake of Energy) trial. Noteworthy features of the CALERIE trial are the substantial size of the trial, the comprehensive physiologic, psychologic, quality of life, and cognitive assessments conducted, as well as the extensive collection of biological samples which include serum, plasma, urine, and biopsies from skeletal muscle (vastus lateralis) and adipose tissue (subcutaneous abdominal).

Funding Opportunity PA-18-823 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long- term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans.

Funding Opportunity RFA-HD-19-014 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

Notice NOT-EB-18-016 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-189 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-188 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-076 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Web Developer Genomics/Bioinformatics - Cambridge - Permanent Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. Cambridge, England

Funding Opportunity RFA-TR-18-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to invite applications for new applications for the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Network (RDCRN). Each consortium within the RDCRN is intended to advance the diagnosis, management, and treatment of rare diseases. The DMCC will facilitate and support the activities of each Rare Diseases Clinical Research Consortium (RDCRC) along with trans-network activities that broadly facilitate the advancement of rare disease research via four Cores; 1) Administrative; 2) Data Management; 3) Clinical Research and; 4) Engagement and Dissemination.

Funding Opportunity RFA-TR-18-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite new and re-competing applications to apply to the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance the diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness. Each RDCRC will promote highly collaborative, multi-site, patient-centric, translational and clinical research with the intent of addressing unmet clinical trial readiness needs.

Funding Opportunity RFA-AG-19-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging is pursuing this initiative to recruit new investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (RFA-AG-19-018).

Funding Opportunity RFA-AG-19-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging is pursuing this initiative to recruit new investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (FOA #).

Funding Opportunity RFA-FD-18-024 from the NIH Guide for Grants and Contracts. The Cooperative Agreement will build upon the extensive experience of an institution with well-established and globally recognized collaboration with inspectorates of National Regulatory Authorities (NRAs) around the globe in support of data-driven and science-based regulatory and public health strategies and approaches that align with FDA domestic and global priorities to assure a pharmaceutical quality integration of assessment, inspection, policy, and research activities within a pharmaceutical context, including Good Manufacturing Practices (GMP). The funding will catalyze and support the institution's activities that are focused on consensus around what optimal good manufacturing practices are and the competencies for Inspectors within the context of emerging and increasingly complex science, research and innovation in manufacturing of pharmaceutical products. Based on such consensus, the institution and its network of NRA Inspectorates will work toward a systems-approach and sustainable alignment across and among NRA Inspectorates in GMP quality manufacturing.

Funding Opportunity RFA-MH-19-201 from the NIH Guide for Grants and Contracts. This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community. This FOA should be used for applications that are not collaborative between sites. Applications requiring two or more collaborating sites to complete the proposed research should apply as a linked set of collaborative U01 applications to the companion collaborative U01 FOA (RFA-MH-19-201). All awards supported under this FOA and the companion collaborative U01 FOA (RFA -MH-19-201) will be governed by the Mental Health Rare Genetic Disease Network (MHRGDN).

Funding Opportunity RFA-MH-19-200 from the NIH Guide for Grants and Contracts. This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community. This FOA should be used for applications that are not collaborative between sites. Applications requiring two or more collaborating sites to complete the proposed research should apply as a linked set of collaborative U01 applications to the companion collaborative U01 FOA (RFA-MH-19-201). All awards supported under this FOA and the companion collaborative U01 FOA (RFA -MH-19-201) will be governed by the Mental Health Rare Genetic Disease Network (MHRGDN).

Funding Opportunity PA-18-821 from the NIH Guide for Grants and Contracts. The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s). Applicants are strongly encouraged to discuss potential requests with the NCI scientific contacts listed below.

Funding Opportunity RFA-AG-19-008 from the NIH Guide for Grants and Contracts. This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.